Latest American Society of Hematology Stories
Learn about ICD10 and regulatory compliance by visiting the Miraca booth. Dallas, Texas (PRWEB) October 29, 2013 Miraca Life Sciences (MLS), the leading
New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic leukemia (ALL).
The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care.
- The act of sweetening by admixture of some saccharine substance.